The FLAIR Study is evaluating a potential new treatment for asthma in children, teens, and adults. Researchers are studying how well it controls symptoms and prevents attacks.
Eligibility:
• Ages 4 and up
• Diagnosed with asthma for at least 1 year
• Had one or more asthma attacks requiring treatment in the past 12 months
This study is testing a new blood test that may help in diagnosing Alzheimer’s disease more easily and earlier in the disease process.
Eligibility:
• Ages 60+
• Diagnosed with Alzheimer’s disease
• MMSE score of 24 or below
This study is designed for individuals with moderately to severely active ulcerative colitis. It aims to assess a new treatment’s impact on symptoms and overall disease progression.
Eligibility:
• Diagnosed with ulcerative colitis for at least 90 days
• Diagnosis confirmed by recent endoscopy and biopsy
This research study evaluates Xanamem®, an investigational treatment for Alzheimer’s disease. The goal is to see if it can help individuals with mild to moderate dementia.
Eligibility:
• Ages 50+
• Diagnosed with mild or moderate dementia due to Alzheimer’s
• Must have a caregiver who can attend all study visits
This study is for participants who previously completed a KarXT study and aims to assess the long-term safety and tolerability of KarXT in individuals with psychosis associated with Alzheimer’s disease.
Eligibility:
• Ages 55–90
• Must have completed study KAR-031 or KAR-032
• Must have a caregiver or study partner who can attend all visits
This study will test the safety and effectiveness of survodutide in treating cirrhosis caused by MASH. The goal is to see if the medication can prevent or delay liver complications and improve long-term outcomes.
Eligibility:
• Ages 18+
• Biopsy-confirmed compensated cirrhosis due to MASH (within past 5 years)
This study investigates a drug called Pegozafermin to see if it can safely treat people with compensated cirrhosis caused by MASH. Researchers will evaluate its effect on liver health and related symptoms.
Eligibility:
• Ages 18–75
• Diagnosed with MASH and biopsy-confirmed compensated cirrhosis (fibrosis stage F4)
This study is evaluating whether an investigational treatment may help people with MASH (formerly NASH) who have stage F2 or F3 liver fibrosis. The goal is to determine if the treatment can improve liver health and slow disease progression.
Eligibility:
• Ages 18+
• Diagnosed with MASH and fibrosis stage F2–F3 confirmed by biopsy (recent or within 6 months)
We understand that enrolling in a clinical trial can raise many questions. How long will the trial last? Are there costs involved? What happens if the treatment doesn’t work for me? Our comprehensive FAQ section is here to address these concerns and more, empowering you with the knowledge you need to make an informed decision. Our goal is to provide answers with empathy and honesty, ensuring you feel supported at every stage of your trial participation. For further details or specific concerns, Read More FAQs to explore all the insights available.
Office Location
9380 SW 150th Street
Suite 140
Miami FL 33176
(786) 310-7477
